Unknown NA INTERVENTIONAL 2-arm NCT05770635

Polyvinyl Alcohol Embolization Microspheres

A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of Polyvinyl Alcohol Embolization Microspheres for Transarterial Chemoembolization of Primary Liver Cancer

Sponsor: Shanghai Huihe Medical Technology Co., Ltd

Conditions Primary Liver Cancer

Interventions Embosphere and chemotherapy drug Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug

Updated 4 times since 2023 Last updated: Mar 5, 2023 Started: Dec 28, 2022 Primary completion: Dec 28, 2024 Completion: Dec 28, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Primary Liver Cancer and is currently ongoing. Shanghai Huihe Medical Technology Co., Ltd leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Apr 2025 — Present [monthly]

Unknown NA

Status: Enrolling By Invitation → Unknown
Sep 2024 — Apr 2025 [monthly]

Enrolling By Invitation NA
Jul 2024 — Sep 2024 [monthly]

Enrolling By Invitation NA
Apr 2023 — Jul 2024 [monthly]

Enrolling By Invitation NA

First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Huihe Medical Technology Co., Ltd

Data source: Shanghai Huihe Medical Technology Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China